MedPath

Irreversible Electroporation for treatment of unresectable, locally advanced pancreatic cancer in the Leiden University Medical Center: a phase I/II study

Conditions
ocally advanced unresectable pancreatic cancer, alvleesklierkanker, lokaal uitgebreid
Registration Number
NL-OMON21164
Lead Sponsor
eiden University Medical Centre
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

1.18 years of age;

2.Tumour in the pancreas suspected for adenocarcinoma;

Exclusion Criteria

1.Contraindications for laparotomy or IRE

2.Resectable at laparotomy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety and feasibility of the procedure. The safety is checked by reporting adverse events, also the first 5 procedures will be filmed. The feasibility is measured by evaluating specific questions about procedure and technical aspects. This is evaluated after every procedure.
Secondary Outcome Measures
NameTimeMethod
- Local progression free survival, based on CT scans. Once pre-procedural, than 5days after, 3,6,9,12,18,24 months after the procedure. <br /><br>- Overall survival in days - day of surgery untill day of death<br /><br>- Tumour downstaging/follow-up of local situation, based on repeated CT scans<br /><br>- NRS pain score; this will be measured daily post-operative. Outcomes will be compared with a control group of patients treated before this trial. <br /><br>- Hospital stay (days: form day of procedure till day of discharge)<br /><br>- Tumour response related to immune defence (blood samples). Once pre-procedural, than 5days after, 3,6,9,12,18,24 months after the procedure.<br /> <br>- Quality of life; as measured by EORTC questionnaire. Once pre-procedural, than 3,9, 18 months after the procedure.
© Copyright 2025. All Rights Reserved by MedPath